2[2]Ferendelli JA. Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy[J ]. Neurology,1995, 45(Suppl 2): S12～ 16.
3[3]Lammers NW, Hekster YA, Keyser A, et al. Monotherapy of polytherapy for epilepsy revisited: a quantitative assessment[J ].Epilepsia, 1995, 36 (5): 440 ～ 446.
4[4]Perucca E. Drug interactions: In: Laidlaw JA. Textbook of epilepsy[M]. Edinburgh:Livingstone Churchill, 1982.362.
5[5]Kutt H. Interactions between anticonvulsants and other com monly prescribed drugs. Epilepsia, 25(Suppl 2): S118～ 123.
6[6]Bourgeois BFD. Antiepileptic drug combinations and experimen tal backgroud:the case of phenobarbitaland phenytoin[J]. ArchPharmacol, 1986, 333:406 ～411.
7[7]Browne TR, Szabo GK, Evans JE, et al. Carbamazepine in crease phenytoin serum concentration and reduces phenytoin clearance[J]. Neurology, 1988, 38:1148～ 1149.
8[8]Levy RH, Pitlick WH. Carbamazepine: interations with other drugs [ M ]. In: woodbury DM. Antiepileptic drugs. New York: Reven Press, 1982. 497 ～ 505.
9[9]Morris JC, Dodson WE, Hatlelid JM, et al. Phenytoin and car bamaxepine alone and in combination: anticonvulsant and neurotoxic effects[J]. Neurology, 1987, 37:1111～ 1118.
10[10]Tsanaclis LM, Allen J, Pemcca E, et al. Effect of valproate on free plasma phenytoin concentrations[J]. Br J Clin Pharmacol, 1984, 18:17～20.
